Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C

Journal of Hepatology

Volumn 39, Issue 6, 2003, Pages 1063-1069

  Asahina, Yasuhiro ^a   Izumi, Namiki ^a   Uchihara, Masakatsu ^a   Noguchi, Osamu ^a   Nishimura, Yuki ^a   Inoue, Kazunari ^a   Ueda, Ken ^a   Tsuchiya, Kaoru ^a   Hamano, Kosei ^a   Itakura, Jun ^a   Miyake, Shozo ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

Case control study; Hepatitis B e antigen; Hepatitis B virus; Therapy; Viral mutation

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DNA DETERMINATION; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; PROMOTER REGION; SEROCONVERSION; VIRUS CORE; VIRUS MUTATION;

EID: 0346850794     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00467-7     Document Type: Article

References (38)

1. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001;34:590-594.
2. Kao JH, Hepatitis B. viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-650.
3. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-559.
4. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001;33:218-223.
5. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122:1756-1762.
6. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002;76:5985-5992.
7. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19-26.
8. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002;36:303-304.
9. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′- thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-8499.
10. Dienstag JL, Perrillo RP. Schiff ER. Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
11. Chayama K, Suzuki Y, Kobayashi M. Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-1716.
12. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639.
13. Carman WF, Jacyna MR, Hadziyannis S. Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2: 588-591.
14. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990;64:1298-1303.
15. Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schroder CH. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol 1993;67:3756-3762.
16. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994;68:8102-8110.
17. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996;70:5845-5851.
18. Yu X, Mertz JE. Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated. J Virol 1996;70:8719-8726.
19. Takahashi K, Aoyama K, Ohno N, Iwata K, Akahane Y, Baba K, et al. The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995;76:3159-3164.
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
21. Mizokami M, Nakano T, Orito E, Tanaka Y, Sakugawa H, Mukaide M, et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999;450:66-71.
22. Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, et al. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J Clin Microbiol 1999;37:310-314.
23. Ide T, Kumashiro R, Hino T, Murashima S, Ogata K, Koga Y, et al. Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine. Hepatol Res 2001;21:76-84.
24. Aritomi T, Yatsuhashi H, Fujino T, Yamasaki K, Inoue O, Koga M, et al. Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan. J Gastroenterol Hepatol 1998;13:1125-1132.
25. Kobayashi S, Shimada K, Suzuki H, Tanikawa K, Sata M. Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif). Hepatol Res 2000;17:31-42.
26. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-194.
27. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A 1-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
28. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
29. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.
30. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120: 1828-1853.
31. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117.
32. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806.
33. Suzuki F, Suzuki Y, Tsubota A, Akuta N, Someya T, Kobayashi M, et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 2002; 37:824-830.
34. Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000;32:1163-1169.
35. Asahina Y, Enomoto N, Ogura Y, Kurosaki M, Sakuma I, Izumi N, et al. Sequential changes in full-length genomes of hepatitis B virus accompanying acute exacerbation of chronic hepatitis B. J Hepatol 1996;25:787-794.
36. Asahina Y, Enomoto N, Ogura Y, Sakuma I, Kurosaki M, Izumi N, et al. Complete nucleotide sequences of hepatitis B virus genomes associated with epidemic fulminant hepatitis. J Med Virol 1996;48: 171-178.
37. Asahina Y, Enomoto N, Nagayama K, Kurosaki M, Ogura Y, Izumi N, et al. Hepatitis B virus mutations associated with lamivudine therapy in patients with chronic hepatitis B. Hepatol Res 1999;15: 145-156.
38. Kurosaki M, Enomoto N, Asahina Y, Sakuma I, Ikeda T, Tozuka S, et al. Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B. J Med Virol 1996;49:115-123.